First Patient Enrolled in OncoQuest’s Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer.
Wednesday, July 19, 2017
Quest PharmaTech Inc., an Edmonton-based pharmaceutical company, announce the appointment of Mark Lievonen, to the company's Board of Directors.
Exciton Technologies Receives Approval from China Food and Drug Administration
Licensing agreement will ensure MMDx becomes the standard of care for transplant patients.
New partnerships with the University Hospital Foundation and leading pharmaceutical companies, Servier and Merck, will help dozens of Alberta health innovators market their discoveries to the world.
Edmonton’s General Intermediates of Canada Inc. (GIC) announced they have successfully completed a research project related to a key starting API material for a global pharmaceutical client.
This research unit designs and performs pragmatic trials and research projects that harness the power of real-world health data.
Yesterday the innovative pharmaceutical industry and the Government of Alberta solidified a collaboration to ignite the life sciences sector in Alberta.
Legislation creating two credits: CITC & AITC will support at least 9,000 jobs and add $1.2 billion to Alberta’s GDP.
The Canada-Alberta Job Grant (CAJG) is a funding program where employers and government share the cost of training new and existing employees to increase their knowledge and skills to meet the needs of Alberta’s changing economy.